Monodermal teratomas of the ovary can take the form of carcinoid tumors of which there are several types, mucinous carcinoid being the least common. Very few cases of primary mucinous carcinoid of the ovary have been reported in the literature and the behavior of these tumors over the long term is unclear. We describe a case of primary mucinous carcinoid of the ovary in a 39-year-old woman treated with unilateral salpingo-oophorectomy, where a metastasis occurred in the contralateral ovary ten years later. This case demonstrates that mucinous carcinoid of the ovary can metastasize even after a long interval, and careful follow-up of patients, particularly those treated conservatively, is appropriate.
Introduction
Fewer than thirty cases of primary mucinous carcinoid of the ovary have been described in the literature and the clinical behavior of this tumor has not been well defined. 1, 2 We describe a patient treated by unilateral oophorectomy who presented with a metastasis in the contralateral ovary more than ten years later.
Case Report
A 39-year-old woman presented with weight loss and abdominal distention and was found to have a pelvic-abdominal mass. Her previous history included an appendectomy 27 years earlier and a negative laparoscopy four years previously. At laparotomy there was a 10 cm mass originating from the left ovary, and a left salpingo-oophorectomy was performed. The uterus and right ovary appeared normal at operation, as did the peritoneum, liver, diaphragm, and lymph nodes. A diagnosis of mucinous carcinoid of the left ovary was made after postoperative gastroscopy, computer tomography (CT) scan, mammography, ultrasound scan of the liver, and urine test for the serotonin metabolite 5-HIAA proved negative. In the light of these negative findings, and given a strong desire on the part of the patient for children, a decision was made to treat her conservatively.
The patient was followed up for ten years but shortly after, now 49 years old, she presented with constipation and abdominal discomfort. A CT scan showed a mass measuring 15¥10 cm originating from the right ovary. A right salpingo-oophorectomy and partial omentectomy were performed; no abnormalities were seen on the peritoneum, liver, or diaphragm at operation and there was no obvious lymph node swelling. A histological diagnosis of metastatic mucinous carcinoid was made. Currently, five years after the second laparotomy, the patient remains well.
Pathological findings

Macroscopic appearances
The first tumor, from the left ovary, weighed 394 g and measured 9.0 cm in maximum diameter (sampled in nine blocks). The cut surface was partly solid and homogeneous with a light brown color and partly cystic. The right ovarian tumor, removed ten years later, was 19 cm in diameter and weighed 1900 g (sampled in 20 blocks). This lesion was predominantly cystic, with a solid area of 5 cm in diameter.
Microscopic appearances
The original tumor from the left ovary showed predominantly small, round glands lined by cells with globules of intracytoplasmic mucin, lying in a collagenous stroma ( Figure  1A ) or floating in lakes of mucin. In most of the tumor the epithelial cell nuclei were small and basal with not more than mild atypia ( Figure  1B) . In some areas, however, the glands were lined with more obviously atypical cells ( Figure  1C ). Here the glands lay closer together, sometimes abutting on one another. In one area there were smaller glands with some cell nests and individual signet ring cells. There was no severe cytological atypia, solid growth of tumor cells or necrosis. An occasional cystic space was present lined by goblet cells with some stratification. Mitotic activity in the more atypical areas reached 10 mitoses per 10 HPF. Elsewhere in the tumor the mitotic rate was lower but varied, with some areas showing 6 mitoses per 10 HPF.
The metastatic tumor from the right ovary showed round glands with an epithelial lining that included goblet cells. Between the goblet cells cylindrical cells with granular eosinophilic cytoplasm were present. Occasionally there were glands with small basal nuclei with mild atypia, but in most areas the glands showed a moderate epithelial atypia ( Figure  2 ). In some areas the glands lay closer together, but nowhere was there a confluent growth pattern or cribriform growth. There were no solid areas. Individual signet ring cells in the stroma were not a feature of this tumor. The cysts seen macroscopically were a prominent feature and were lined by the same cell population as the small glands, often with multi layering (Figure 2 ). Fairly extensive areas of necrosis were present, involving glands and stroma and interpreted as infarction rather than true tumor necrosis. Mitotic activity was focally brisk, 17 per 10 HPF. In neither of the specimens was there any other tumor component (for example, struma or other carcinoid type or mature teratoma component) identified. No vascular or lymphatic invasion was identified.
Immunohistochemistry
Epitope retrieval was heat-induced and the buffer used was tris-EDTA, pH 9. Both tumors showed positivity for chromogranin (Biogenics LK2H10, 1;200). In the primary tumor, staining varied from sporadic cells in some areas to staining of several cells in every gland in other areas. In the metastasis, almost all glands showed staining, varying from a few cells to 50% of the cells in the gland ( Figure 3A cells were found in the metastasis. NSE (Dako BBS/NC/V1H14, 1:50) and CD56 (Neomarker 123c3.D5, 1:25) staining were negative.
Molecular biology
To determine the relationship between the two tumors, loss of heterozygosity (LOH) analysis was performed. The area of the primary tumor showing the most cytological and architectural atypia was selected for analysis. Sixteen microsatellite markers on 12 different chromosomes were investigated for LOH. With four microsatellite markers on four different chromosomes, LOH was observed. An identical pattern of loss in both tumors was found with two microsatellite markers, D8S133 on chromosome 8p and AFMa086WG9 in intron1 of the PTEN gene on 10q. In addition, there was LOH identified only in the later tumor with markers D11S419 on chromosome 11p and D13S1307 on 13q.
Discussion
Mucinous carcinoid is an unusual tumor in the ovary and has been described more often as metastatic from the appendix than as a primary lesion. [3] [4] [5] [6] [7] [8] [9] [10] [11] Distinguishing primary ovarian carcinoid from metastatic carcinoid can be very difficult. Primary carcinoids of the ovary are generally unilateral. Metastatic carcinoids are nearly always bilateral and scattered tumor deposits are present throughout both ovaries. 3 In the case we describe, the appendix had been removed 27 years before the first ovarian tumor occurred, effectively excluding the appendix as the primary. After the initial surgery, extensive investigation failed to reveal any tumor elsewhere and no other primary has manifest itself in the following 15 years.
We regard the second ovarian tumor as a metastasis, and not as a second primary, on the grounds of the similar histological picture and the findings of the molecular biology analysis. Immunohistochemical staining for chromogranin was positive, and there was scanty staining for synaptophysin in the first tumor. These immunohistochemical stains can support neuroendocrine differentiation, but are not specific for mucinous carcinoid. The morphology is also of key importance. The fact that two identical markers were lost points to the tumors being the same entity. The new abnormalities in the metastatic tumor would represent further chromosomal abnormalities acquired during the progression of the tumor. Our patient did not receive adjuvant chem otherapy after her second operation, because the literature suggests surgical resection of recurrent disease for ovarian carcinoid tumors, 12, 13 and to our knowledge there is no clear literature on management of metastatic mucinous carcinoid.
The paucity of cases described in the literature means that the behavior of ovarian mucin ous carcinoid is not clearly defined. Baker et al. 1 described 17 cases that they subdivided into three groups, initially characterized by them as grade 1, 2, and 3 but ultimately classified as well-differentiated, atypical, and carcinoma arising in mucinous carcinoid, in an attempt to conform to the terminology used in appendiceal carcinoid. They then attempted to correlate the histological type with the behavior. These authors observed a gradation in mitotic activity, cytological atypia, and architectural abnormality along the spectrum of lesions they describe. They commented that although they found no metastases in their "well-differentiated'' or "atypical'' cateCase Report gories they nevertheless suspect that these lesions have a low malignant potential. Two cases were categorized as carcinoma arising in mucinous carcinoid, both more than stage I, and were fatal within one year. All other patients, even within this category, were stage I and remained well. No cases of late metastasis were observed in this series.
Our case showed areas in the primary tumor that probably can best be classified as atypical according to the categorization of Baker et al., 1 although the bulk of the tumor was well differentiated. The metastasis showed much more widespread cytological atypia; however, the severe cytological atypia, solid growth pattern, and tumor-type necrosis described by Baker et al1 in their examples of carcinoma arising in mucinous carcinoid were not apparent. The tumors we describe are difficult to place exactly in the categories described by Baker et al., 1 but the atypical histological features coupled with the prolonged clinical course seem to match their suggestion of a spectrum of histological abnormality and clinical behavior in these lesions. On the basis of the case described here we suggest that any atypical architecture or increased mitotic activity, even focally, signals a need for caution in assessing prognosis.
Take home messages: 1. Primary mucinous carcinoid in the ovary is a rare tumor and should be diagnosed only after rigorous exclusion of a primary elsewhere. 2. The course of the disease may be prolonged with metastases after many years. 3. Atypical architecture or increased mitotic activity, even focally, signals a need for caution in assessing prognosis.
Introduction
Type IV osteolysis or Gorham-Stout syndrome is a rare variant of idiopathic osteolytic disease.
1 In 1838 Jackson first described the disease in an 18-year-old man with a gradually vanishing humerus. 2 Later, in 1955 Gorham and Stout identified and reported 16 patients with similar disease.
3 Gorham-Stout syndrome is characterized by progressive angiomatosis of venous, capillary, or lymphatic origin. [4] [5] [6] The pathology of Gorham-Stout syndrome is associated with angiomatosis coupled with active osteolysis resulting in vascular tumor replacement of bone. The osteolysis can be monostotic or polyostotic and has the potential to result in the physical loss of entire bones -hence the term "vanishing bone disease." Involution and resolution, whether spontaneous or treatment induced, will result in replacement of the lesion with connective tissue; thus changing the underlying anatomy and physiology of the region. Often, presentation of Gorham-Stout syndrome is a consequence of the compromised skeletal framework. 1, 7 Anatomical malformations and pathological fractures are often seen as common symptoms of presentation. Other presenting signs or symptoms are associated with underlying inflammation, such as fatigue and generalized pain. 7 Diagnosis is a combination of clinical suspicion with supportive imaging, but is confirmed by histopathological analysis of the lesions. Biopsy always shows extensive nonmalignant hyperproliferation of small vessels. 1, 5, 7 
Gorham-Stout Syndrome Review
Gorham-Stout syndrome has been described in all anatomical locations and tissue types, but is seen most commonly in the anatomical girdles (pelvic or shoulder) or in the long bones of the extremities. Rarely, soft tissue or skin lesions are seen and their presence reflects an increased severity of disease. One review noted that only five of the 220 (2.27%) reported cases of Gorham-Stout syndrome had cutaneous involvement in their disease. 5 When present, soft tissue lesions are reflective of involved bone distribution. 5 Patient age ranges have been reported from one month to 75 years, 1 with children and young adults being most commonly afflicted. To date, there has not been an epidemiologic correlation with race, gender, or geography. [7] [8] [9] [10] Originally, Gorham and Stout postulated the tumors to be secondary to progressive hemangiomatosis. 3, 10 The etiology is largely unknown but is thought to be multifactorial. Review of current literature yielded many possible etiological factors. In summary, GorhamStout syndrome is thought to result from a complex interaction between growth factors, angiogenic factors, and inflammatory mediators. A previous study identified histological markers on the characteristic cells of GorhamStout syndrome that indicate a monocyte lineage. 11 These so-called Gorham cells (GCs) have been shown to respond to known osteoclastic and angiogenic factors resulting in disease specific pathology. In particular, vascular endothelial growth factor (VEGF) subtypes, platelet-derived growth factor subtypes (PDGF), and inflammatory cytokines (TGF, IL-6, and IL-1) lead to increased activity of the GCs. 11, 12 In 2006 Bruch-Graher and colleagues argued a lymphatic origin of the angiomatosis leading to lesion formation. 5 The majority of cases reported show spontan eous resolution of disease for unknown reasons. 4, 14, 15 However, rare cases of chronic recurrent angiomatosis have been reported, many ultimately resulting in death. Chylothorax and spinal cord compression are two of the more severe examples of complications resulting from chronic disease. Chylothorax results from occlusion of the large lymphatic vessels in the thorax and in turn leads to fluid collection. 5, 10, 11 Osseous degeneration of the vertebrae leads to skeletal framework compromisation and spinal cord compression. Prompt therapeutic intervention is recommended with evidence of lymphatic or vertebral invasion. 1, 7, 10, 16, 17 There is no known cure for Gorham-Stout syndrome and as such treatment depends on patient specific variables. Historically, local control was the primary therapeutic goal for recurrent disease. Classically, local disease was managed with a combination of surgical resection or radiation therapy. 10, [18] [19] [20] [21] Investigation of the literature indicates radiotherapy to be the best option to halt disease progression, with reported results showing foci of bone regrowth. 7, 10, [18] [19] [20] [21] Investigation into the pathophysiology behind Gorham-Stout syndrome has resulted in an evolution in treatment options targeting proposed pathophysiological pathways. For example, bisphosphonate therapy has been shown to decrease osteolytic
